NIFTY 50 23345.4 ▲ (0%)
NIFTY NEXT 50 64826.45 ▼ (0.43%)
NIFTY 100 24030.7 ▼ (0.08%)
NIFTY MIDCAP 100 54960.95 ▼ (0.26%)
NIFTY SMALLCAP 100 17879.05 ▲ (0.08%)
NIFTY SMALLCAP 250 16861.25 ▲ (0.12%)
NIFTY MIDCAP SELECT 12282.8 ▼ (0.6%)
NIFTY TOTAL MARKET 12299.3 ▼ (0.04%)
NIFTY BANK 49212.3 ▼ (0.28%)
SENSEX 76880.92 ▼ (0.25%)
BSE BANKEX 55826.07 ▼ (0.38%)

Mankind Pharma : Q4 2024 Financial Quarterly Report : YoY Sales Up 14.99 %, QoQ Down 8.73 %

May 17, 2024May 17, 2024| adminadmin| 0 Comments| 4:58 pm
Image is loading
Categories:

Share the post "Mankind Pharma : Q4 2024 Financial Quarterly Report : YoY Sales Up 14.99 %, QoQ Down 8.73 %"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter: The company experienced a substantial growth of 14.99 % in the past year, decrease in net sales/revenue by -8.73 %.
  • Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 97.48 %. Marginal increase in other income during this quarter, up by 24.72%.
  • Profit over the Year and quarter: Significant improvement in profitability for Mankind Pharma Limited. Notable increase of 61.63 % in net profit Year to Year, Mankind Pharma Limited’s profitability dropped by -6.76 % Quarter to Quarter.
  • EPS over the Year and quarter: EPS increased by 61.77 % Year to Year. EPS decreased by -6.74 % in previous quarter. Analysis needed for shareholder value.

The comprehensive analytics outlining the performance and outlook of Mankind Pharma Limited”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 1872.122 Cr Rs. 2358.566 Cr Rs. 2152.687 Cr -8.73 % + 14.99 %
Expenses Rs. 1490.96 Cr Rs. 1755.46 Cr Rs. 1605.35 Cr -8.55 % + 7.67 %
Operating Profit Rs. 381.16 Cr Rs. 603.11 Cr Rs. 547.34 Cr -9.25 % + 43.6 %
OPM % 20.36 % 25.57 % 25.43 % -0.14 % + 5.07 %
Other Income Rs. 42.46 Cr Rs. 67.23 Cr Rs. 83.85 Cr + 24.72 % + 97.48 %
Interest Rs. 0.89 Cr Rs. 4.26 Cr Rs. 4.04 Cr -5.16 % + 353.93 %
Depreciation Rs. 67.3 Cr Rs. 89.73 Cr Rs. 82.29 Cr -8.29 % + 22.27 %
Profit before tax Rs. 355.43 Cr Rs. 576.35 Cr Rs. 544.86 Cr -5.46 % + 53.3 %
Tax % 20.95 % 15.49 % 16.64 % + 1.15 % -4.31 %
Net Profit Rs. 280.99 Cr Rs. 487.07 Cr Rs. 454.17 Cr -6.75 % + 61.63 %
EPS in Rs Rs. 7.01 Rs. 12.16 Rs. 11.34 -6.74 % + 61.77 %


Today, we’re looking at Mankind Pharma Limited’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 14.99 %. However, it did see a marginal slip of -8.73 % from the previous quarter. Expenses decreased slightly by -8.55 % quarter-on-quarter, aligning with the annual rise of 7.67 %. Operating profit, while up 43.6 % compared to last year, faced a quarter-on-quarter dip of -9.25 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 5.07 %, but a shrinkage of -0.14 % sequentially. Other income rose by 24.72 % compared to the last quarter, despite an annual growth of 97.48 %. Interest expenses dropped significantly by -5.16 % from the previous quarter, yet the year-over-year increase remains at a moderate 353.93 %. Depreciation costs fell by -8.29 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 22.27 %. Profit before tax grew annually by 53.3 % but saw a reduction from the preceding quarter by -5.46 %.
Tax expenses as a percentage of profits decreased slightly by -4.31 % compared to last year, with a more notable quarter-on-quarter increase of 1.15 %. Net profit rose by 61.63 % year-on-year but witnessed a -6.75 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 61.77 % but a quarterly fall of -6.74 %. In summary, Mankind Pharma Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 1872.122 Cr Rs. 2358.566 Cr Rs. 2152.687 Cr -8.73 % + 14.99 %
Expenses Rs. 1490.96 Cr Rs. 1755.46 Cr Rs. 1605.35 Cr -8.55 % + 7.67 %
Operating Profit Rs. 381.16 Cr Rs. 603.11 Cr Rs. 547.34 Cr -9.25 % + 43.6 %
Net Profit Rs. 280.99 Cr Rs. 487.07 Cr Rs. 454.17 Cr -6.75 % + 61.63 %
EPS in Rs Rs. 7.01 Rs. 12.16 Rs. 11.34 -6.74 % + 61.77 %


In reviewing Mankind Pharma Limited’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 14.99 % year-on-year growth, although there was a slight dip of -8.73 % from the previous quarter. Expenses rose by 7.67 % compared to the previous year, with a decrease of -8.55 % quarter-on-quarter. Operating Profit surged by 43.6 % annually, and saw a -9.25 % decrease from the last quarter.
Net Profit showed yearly increase of 61.63 %, and experienced a -6.75 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 61.77 % annually, however dipped by -6.74 % compared to the last quarter. In essence, while Mankind Pharma Limited exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”Mankind Pharma “]

Related Post